DEAD/H-box helicase 11 like 9 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DDX11L9 profile across patient tissues and cancer cell-line models. DDX11L9 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, DDX11L9 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, DDX11L9 RNA expression shows 4,310 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, BRCA, and TGCT as cancer lineages where DDX11L9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX11L9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX11L9 survival associations across molecular data types. DDX11L9 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX11L9 RNA expression–survival associations across cancer types. High DDX11L9 expression shows unfavorable associations in UCS, KIRP, KICH, LIHC, KIRC and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for DDX11L9 RNA expression.
This table summarizes DDX11L9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DDX11L9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX11L9 shows lower tumor expression in COAD and THCA and higher tumor expression in BRCA. The BRCA box plot shows higher DDX11L9 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .003).
This table shows molecular features associated with DDX11L9 in patient tissues and cancer cell lines. In patient samples, DDX11L9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
